Case Caption: In re Dexilant (Dexlansaprazole) Antitrust Litigation
Court: United States District Court for the Northern District of California
Case Number: 3;25-cv-02785
Judge: Honorable Jacqueline Scott Corley
Plaintiff: Plumbers Local 690 Health Plan
Defendant: Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc., TWi Pharmaceuticals, Inc., TWi Pharmaceuticals USA, Inc., Bora Pharmaceuticals Co. Ltd, and Upsher-Smith Laboratories, LLC
Class Period: June 15, 2020–Present
This antitrust case against brand drug company, Takeda, concerns the drug Dexilant (dexlansoprazole), a proton pump inhibitor used to treat heartburn, gastroesophageal reflux disease, and esophageal damage. In particular, plaintiffs allege that Takeda and TWi, a generic drug company, entered into an unlawful reverse payment settlement, which delayed the launch of a generic version of Dexilant and limited generic competition, resulting in higher prices for third-party payors. The plaintiffs filed a consolidated complaint on August 18, 2025.